Account
Watchlists
Bookmarks
Pricing
Home
Dashboard
Ask Portfolio
Discovery
Timeline
Toolkit
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
Sheel Biotech Limited, incorporated in 1991, is an ISO-certified company specializing in biotechnology and agriculture. The company operates across multiple segments, including the production of plants through tissue culture at its DBT-recognized lab, organic farming under various government schemes, manufacturing greenhouses, and providing green landscaping services. Sheel Biotech also promotes Farmer Producer Organizations (FPOs) to empower farmers and enhance their market access. With a strong focus on research and development, the company leverages Dutch technology at its Manesar facility, which has a production capacity of 10 million plants annually.
Opening Date
Sep 30, 2025
Closing Date
Oct 03, 2025
Listing Date
Oct 08, 2025
IPO Type
SME
IPO Status
Closed
Issue Size
34.02 Cr
Fresh Issue
34.02 Cr
Offer for Sale
—
Price Band
₹59 - ₹63
Lot Size
2000
The main objectives of the issue are to utilize the net proceeds for the following purposes:
Funding capital expenditure of ₹9.12 crores for expanding the current facility in Ghaziabad, Uttar Pradesh, to cultivate blueberries. This includes purchasing 30,000 mother plants, setting up a protected greenhouse structure, fencing, a water reservoir, a packhouse, and cold storage facilities.
Meeting working capital requirements of ₹15.88 crores to support incremental business needs, fund growth opportunities, and manage operational cash flows.
Financing general corporate purposes, which will not exceed 25% of the gross proceeds from the issue, to support overall business growth and strategic initiatives.
P/E Ratio
6.63
EPS
3.22
ROE
13.59%
ROCE
16.34%
RONW
13.59%
Debt to Equity Ratio
0.32
PAT Margin
10.51%
EBITDA Margin
14.71%
P/B
1.26
Diversified business model across tissue culture, organic farming, landscaping, and FPO promotion.
Over 30 years of operational history with an experienced management team and promoters.
Advanced R&D capabilities with a DBT-recognized lab and a large production capacity of 10 million plants.
ISO 9001:2015, 14001:2015 & 45001:2018 certifications, reflecting a commitment to quality and environmental standards.
Significant revenue dependence on government tenders, making the business vulnerable to policy changes.
Operations are subject to seasonal fluctuations which can disrupt project timelines and impact revenues.
History of negative cash flows from operating activities, indicating potential working capital challenges.
The company's registered office is on rented premises, which poses a risk of relocation and operational disruption.
Capitalizing on the growing consumer demand for healthy and organic products, such as blueberries.
Expanding into high-value crop cultivation to diversify product offerings and enhance profitability.
Leveraging various government schemes and initiatives promoting organic farming and FPOs for further growth.
Tapping into the growing global and domestic plant tissue culture market.
Inherent risks in tissue culture, such as contamination and temperature variations, which can affect production.
Changes in government policies, budget allocations, or delays in tender processes could adversely impact revenue.
Intense competition from other players in the biotechnology and agri-business sectors.
Macroeconomic factors like economic slowdowns, inflation, and pandemics can negatively affect business operations.